[Polymorphism of catechol-O-methyltransferase gene in relation to the risk of endometrial cancer].Zhonghua Fu Chan Ke Za Zhi 2007; 42(2):116-9ZF
The 4- and 16-hydroxylated metabolites of estrogens have been implicated in carcinogenesis, whereas its 2-hydroxylated metabolites have been shown to have antiangiogenic effects. We aimed to examine whether the polymorphisms of catechol-O-methyltransferase (COMT) involved in the estrogen metabolism are associated with endometrial cancer risk.
Polymerase chain reaction-restrictive fragment length polymorphism (PCR-RFLP) analysis was used to study the variant allele frequency distributions of COMT Val158Met genetic polymorphism in a population based case-control study with 132 endometrial cancer cases and 110 controls. Odds ratios (OR) and 95% confidence intervals (CI) were estimated by unconditional logistic regression after adjustment for known or suspected risk factors for endometrial cancer.
The most frequent genotype was COMT(Val/Val) (47.2%, 52/110) in control group and COMT(Val/Met) (58.3%, 77/132) in endometrial cancer group. The difference between the two groups was of statistical significance (P < 0.05). Compared with COMT(Met/Met) genotype, the COMT(Val/Val) genotype was inversely correlated with endometrial cancer risk, and the adjusted OR value was 0.262 (95% CI: 0.080 - 0.862, P = 0.027).
Among the genotypes in women in South China, genotype COMT(Val/Val) is mostly seen, followed by COMT(Val/Met), and COMT(Met/Met) is the least in control group. The endometrial cancer susceptivity of genotype COMT(Val/Val) carriers may be lower than COMT(Met/Met) carriers.